Psychiatry and Neurology, Neurology · Royal Oak, MI
NPI
1477758712
Since 2007
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
110 E 2nd St
Royal Oak, MI, 48067
Phone (248) 549-2110
Groups this clinician bills Medicare through
Medicare paid, 2024
$15K
178 services
Medicare patients, 2024
105
Average age 67
Drug cost, 2024
$1.1M
1,489 prescriptions
Company payments, 2025
$275
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vibhangini S Wasade was code 95720 (neurologic), 47 times for 23 patients. In total Vibhangini S Wasade billed 178 services in 15 codes, and Medicare paid $15K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-09-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95720 Neurologic | Facility | 47 | 23 | $152.70 | $7,177 |
| 95816 Neurologic | Facility | 28 | 28 | $39.62 | $1,109 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 26 | 22 | $11.84 | $308 |
| 99215 Office E&M - Established | Office | 20 | 16 | $96.71 | $1,934 |
| 95718 Neurologic | Facility | 12 | 12 | $98.33 | $1,180 |
By year: 2022 $18K for 215 services; 2023 $18K for 200 services; 2024 $15K for 178 services.
Medicare prescription drug claims, 2024
In 2024, the drug Vibhangini S Wasade prescribed most often to Medicare patients was Briviact (Brivaracetam), with 136 prescriptions and refills. In total Vibhangini S Wasade wrote 1,489 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Briviact Brivaracetam | 136 | 179 | 16 | $261K |
| Lamotrigine Generic | 130 | 314 | 21 | $3,450 |
| Levetiracetam Generic | 113 | 266 | 33 | $6,525 |
| Lacosamide Generic | 111 | 191 | 16 | $11K |
| Clobazam Generic | 71 | 94 | Under 11 | $13K |
| Zonisamide Generic | 59 | 110 | 14 | $3,009 |
| Topiramate Generic | 59 | 150 | 14 | $1,646 |
| Levetiracetam Er Levetiracetam | 49 | 93 | Under 11 | $4,950 |
| Clonazepam Generic | 48 | 73 | Under 11 | $415 |
| Epidiolex Cannabidiol (Cbd) | 48 | 50 | Under 11 | $104K |
| Divalproex Sodium Er Divalproex Sodium | 41 | 81 | Under 11 | $3,017 |
| Gabapentin Generic | 33 | 79 | Under 11 | $677 |
| Xcopri Cenobamate | 33 | 34 | Under 11 | $41K |
| Donepezil Hcl Generic | 32 | 76 | 11 | $608 |
| Divalproex Sodium Generic | 30 | 60 | Under 11 | $984 |
Brand drugs: 443 claims; generic drugs: 1,034 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vibhangini S Wasade $275 ($275 in general payments such as food, travel and fees) from 2 companies. The largest payer was UCB, Inc. with $275.
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. UCB.BR | 3 | $275 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.